Meeting
2023 ASCO Annual Meeting
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Authors
Muhit Ozcan
Ankara University School of Medicine, Ankara, Turkey
Muhit Ozcan , Seung Tae Lee , Felix Mensah , Dipenkumar Modi , Alexander Fossa , Won Seog Kim , Ewa Paszkiewicz-Kozik , Yazeed Sawalha , Ömür Gökmen Sevindik , Lalita Norasetthada , Armando Santoro , Kumudu Pathiraja , Samhita Chakraborty , Patricia Marinello , David Lavie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT05144841
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7531)
DOI
10.1200/JCO.2023.41.16_suppl.7531
Abstract #
7531
Poster Bd #
82
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
First Author: David Lavie
Poster
2023 ASCO Annual Meeting
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
First Author: Pier Luigi Zinzani
Poster
2022 ASCO Annual Meeting
Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.
First Author: Patrick Wayne Cobb
